SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 6/19/14 Aurinia Pharmaceuticals Inc. 40FR12B/A 6/18/14 86:8.8M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: 40FR12B/A Amendment to Registration of Securities of a HTML 62K Canadian Issuer -- SEA'34 §12(b) 2: EX-99.1 Miscellaneous Exhibit HTML 27K 11: EX-99.10 Miscellaneous Exhibit HTML 26K 12: EX-99.11 Miscellaneous Exhibit HTML 23K 13: EX-99.12 Miscellaneous Exhibit HTML 23K 14: EX-99.13 Miscellaneous Exhibit HTML 22K 15: EX-99.14 Miscellaneous Exhibit HTML 22K 16: EX-99.15 Miscellaneous Exhibit HTML 365K 17: EX-99.16 Miscellaneous Exhibit HTML 308K 18: EX-99.17 Miscellaneous Exhibit HTML 369K 19: EX-99.18 Miscellaneous Exhibit HTML 426K 20: EX-99.19 Miscellaneous Exhibit HTML 414K 3: EX-99.2 Miscellaneous Exhibit HTML 27K 21: EX-99.20 Miscellaneous Exhibit HTML 186K 22: EX-99.21 Miscellaneous Exhibit HTML 236K 23: EX-99.22 Miscellaneous Exhibit HTML 302K 24: EX-99.23 Miscellaneous Exhibit HTML 200K 25: EX-99.24 Miscellaneous Exhibit HTML 210K 26: EX-99.25 Miscellaneous Exhibit HTML 152K 27: EX-99.26 Miscellaneous Exhibit HTML 166K 28: EX-99.27 Miscellaneous Exhibit HTML 193K 29: EX-99.28 Miscellaneous Exhibit HTML 236K 30: EX-99.29 Miscellaneous Exhibit HTML 139K 4: EX-99.3 Miscellaneous Exhibit HTML 25K 31: EX-99.30 Miscellaneous Exhibit HTML 284K 32: EX-99.31 Miscellaneous Exhibit HTML 24K 33: EX-99.32 Miscellaneous Exhibit HTML 26K 34: EX-99.33 Miscellaneous Exhibit HTML 23K 35: EX-99.34 Miscellaneous Exhibit HTML 33K 36: EX-99.35 Miscellaneous Exhibit HTML 30K 37: EX-99.36 Miscellaneous Exhibit HTML 628K 38: EX-99.37 Miscellaneous Exhibit HTML 296K 39: EX-99.38 Miscellaneous Exhibit HTML 27K 40: EX-99.39 Miscellaneous Exhibit HTML 26K 5: EX-99.4 Miscellaneous Exhibit HTML 25K 41: EX-99.40 Miscellaneous Exhibit HTML 283K 42: EX-99.41 Miscellaneous Exhibit HTML 89K 43: EX-99.42 Miscellaneous Exhibit HTML 280K 44: EX-99.43 Miscellaneous Exhibit HTML 25K 45: EX-99.44 Miscellaneous Exhibit HTML 30K 46: EX-99.45 Miscellaneous Exhibit HTML 31K 47: EX-99.46 Miscellaneous Exhibit HTML 32K 48: EX-99.47 Miscellaneous Exhibit HTML 46K 49: EX-99.48 Miscellaneous Exhibit HTML 26K 50: EX-99.49 Miscellaneous Exhibit HTML 30K 6: EX-99.5 Miscellaneous Exhibit HTML 24K 51: EX-99.50 Miscellaneous Exhibit HTML 28K 52: EX-99.51 Miscellaneous Exhibit HTML 54K 53: EX-99.52 Miscellaneous Exhibit HTML 37K 54: EX-99.53 Miscellaneous Exhibit HTML 30K 55: EX-99.54 Miscellaneous Exhibit HTML 26K 56: EX-99.55 Miscellaneous Exhibit HTML 27K 57: EX-99.56 Miscellaneous Exhibit HTML 24K 58: EX-99.57 Miscellaneous Exhibit HTML 23K 59: EX-99.58 Miscellaneous Exhibit HTML 55K 60: EX-99.59 Miscellaneous Exhibit HTML 25K 7: EX-99.6 Miscellaneous Exhibit HTML 24K 61: EX-99.60 Miscellaneous Exhibit HTML 31K 62: EX-99.61 Miscellaneous Exhibit HTML 26K 63: EX-99.62 Miscellaneous Exhibit HTML 25K 64: EX-99.63 Miscellaneous Exhibit HTML 25K 65: EX-99.64 Miscellaneous Exhibit HTML 57K 66: EX-99.65 Miscellaneous Exhibit HTML 46K 67: EX-99.66 Miscellaneous Exhibit HTML 26K 68: EX-99.67 Miscellaneous Exhibit HTML 26K 69: EX-99.68 Miscellaneous Exhibit HTML 26K 70: EX-99.69 Miscellaneous Exhibit HTML 26K 8: EX-99.7 Miscellaneous Exhibit HTML 26K 71: EX-99.70 Miscellaneous Exhibit HTML 26K 72: EX-99.71 Miscellaneous Exhibit HTML 26K 73: EX-99.72 Miscellaneous Exhibit HTML 26K 74: EX-99.73 Miscellaneous Exhibit HTML 29K 75: EX-99.74 Miscellaneous Exhibit HTML 24K 76: EX-99.75 Miscellaneous Exhibit HTML 24K 77: EX-99.76 Miscellaneous Exhibit HTML 20K 78: EX-99.77 Miscellaneous Exhibit HTML 26K 79: EX-99.78 Miscellaneous Exhibit HTML 36K 80: EX-99.79 Miscellaneous Exhibit HTML 27K 9: EX-99.8 Miscellaneous Exhibit HTML 26K 81: EX-99.80 Miscellaneous Exhibit HTML 31K 82: EX-99.81 Miscellaneous Exhibit HTML 31K 83: EX-99.82 Miscellaneous Exhibit HTML 22K 84: EX-99.83 Miscellaneous Exhibit HTML 23K 85: EX-99.84 Miscellaneous Exhibit HTML 22K 86: EX-99.85 Miscellaneous Exhibit HTML 25K 10: EX-99.9 Miscellaneous Exhibit HTML 26K
Prepared by R.R. Donnelley Financial -- EX-99.57 |
Exhibit 99.57
Aurinia Pharmaceuticals Inc.
NEWS RELEASE
Aurinia Appoints Accomplished Biotech and Pharma Industry
Veteran, Stephen W. Zaruby, as President & CEO
Victoria, BC, November 6, 2013—Aurinia Pharmaceuticals Inc. (TSX-V:AUP) (“Aurinia” or the “Company”) today announced the appointment of Stephen W. Zaruby as the Company’s President and Chief Executive Officer.
Mr. Zaruby has an accomplished history of strategic operations, sales and marketing, research and development, and general management success in the global biotechnology and pharmaceutical industries. Previously, he was President of Seattle-based ZymoGenetics Inc., which was acquired by Bristol-Myers Squibb for US$885 million in 2010. Mr. Zaruby joined ZymoGenetics from Bayer. There, his 20 years of progressive leadership experience included executive roles managing Bayer’s domestic and international anti-infectives, quinolone and hospital/surgical business franchises.
“I am very pleased to have recruited an executive of Stephen’s caliber to this key position with the Company,” commented Aurinia’s Executive Chairman, Dr. Richard Glickman. “Stephen is a seasoned leader with a strong track record of delivering strategic direction and operational excellence to both established and emerging life sciences companies. He is exceptionally qualified to help us build our voclosporin franchise and sharpen our execution.”
Mr. Zaruby said, “Aurinia is well positioned to bring voclosporin forward as an important new treatment for lupus nephritis. I am incredibly energized by this opportunity and look forward to contributing to the new Company’s success.”
About Aurinia
Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. Its lead drug, voclosporin, is a novel calcineurin inhibitor. Many members of Aurinia’s current leadership team are former senior managers of Aspreva Pharmaceuticals (“Aspreva”), which Galenica acquired for C$915 million in 2008. While at Aspreva, this management team executed one of the largest and most important lupus nephritis studies ever conducted, called the Aspreva Lupus Management Study (“ALMS”), which resulted in the emergence of mycophenolate mofetil as a new standard treatment for patients suffering from this devastating and potentially fatal disease. Aurinia holds global rights to all indications for voclosporin and has development and commercialization partners in Canada, Israel, South Africa and Greater China. Aurinia also has a development and commercialization partner for ophthalmologic indications. In addition, Aurinia holds certain rights to exploit the ALMS database. More information is available at www.auriniapharma.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Investor & Media Contact:
Stephen Kilmer
647-872-4849
This ‘40FR12B/A’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed as of: | 6/19/14 | None on these Dates | ||
Filed on: | 6/18/14 | |||
11/6/13 | ||||
List all Filings |